Cosciens Biopharma (CSCI) confirmed that its board of directors has received a letter from Goodwood Fund and Puccetti Funds Management regarding six director nominations for the company’s upcoming annual and special meeting of shareholders. “We respectfully acknowledge receipt of the statement regarding the intentions from Goodwood and are carefully reviewing its contents,” said Ronnie Miller, Chair of the Board of Cosciens Biopharma. “With this in hand, the Board will evaluate and determine its path forward and remains fully committed to acting in the best interests of Cosciens and our shareholders.” The company will continue to provide updates to shareholders related to this matter, it added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSCI:
- COSCIENS Biopharma Receives Director Nominations from Goodwood
- COSCIENS Biopharma Reports Q1 2025 Results and Updates
- COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance
- COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates
- COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts